Daniela Feingold
Overview
Explore the profile of Daniela Feingold including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
53
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Solomon D, Leigh N, Bekhor E, Feferman Y, Dhorajiya P, Feingold D, et al.
Surgeon
. 2021 Jan;
19(6):e379-e385.
PMID: 33423919
Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is effective in select patients with peritoneal metastases of colorectal (CRC) origin. The impact of different biomarkers in predicting recurrence after CRS/HIPEC...
2.
Solomon D, DeNicola N, Feferman Y, Feingold D, Aycart S, Magge D, et al.
J Oncol Pract
. 2019 Jul;
15(8):e739-e745.
PMID: 31260384
Purpose: The American College of Surgeons (ACS) recently published quality assurance (QA) indicators for pancreatic cancer care. Implementing quality indicators in a newly formed health system may lead to better...
3.
Leigh N, Solomon D, Feingold D, Magge D, Golas B, Sarpel U, et al.
Ann Surg Oncol
. 2019 Jun;
27(1):222-231.
PMID: 31222683
Background: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is an aggressive locoregional treatment for peritoneal carcinomatosis (PC). Studies demonstrate improved perioperative and oncologic outcomes at high-volume centers. Methods: This study...
4.
Leigh N, Solomon D, Feingold D, Hiotis S, Labow D, Magge D, et al.
HPB (Oxford)
. 2019 Apr;
21(11):1563-1569.
PMID: 31010632
Background: Current guidelines recommend harvesting a total lymph node count (TLNC) ≥6 from portal lymphadenectomy in ≥pT1b gallbladder cancers (GBC) for accurate staging and prognostication. This study aimed to determine...
5.
Solomon D, DeNicola N, Feingold D, Liu P, Aycart S, Golas B, et al.
J Surg Oncol
. 2019 Jan;
119(6):758-765.
PMID: 30650185
Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is effective in select patients with peritoneal carcinomatosis (PC). Signet ring cell (SRC) pathology is associated with poor prognosis. The role of...
6.
Solomon D, DeNicola N, Feferman Y, Bekhor E, Reppucci M, Feingold D, et al.
Ann Surg Oncol
. 2019 Jan;
26(3):845-851.
PMID: 30643994
Background: Colonoscopy to detect colorectal cancer (CRC) is recommended starting at age 50 years; however, CRC rates are increasing in the prescreening population. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)...
7.
Feferman Y, Solomon D, Bhagwandin S, Kim J, Aycart S, Feingold D, et al.
Ann Surg Oncol
. 2018 Dec;
26(2):482-489.
PMID: 30539491
Background: This report describes patterns of disease recurrence after optimal cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis (PC) of colorectal (CRC) and appendiceal adenocarcinoma (AC) origin. Methods:...
8.
Feferman Y, Bhagwandin S, Kim J, Aycart S, Feingold D, Labow D, et al.
Ann Surg Oncol
. 2017 Oct;
24(13):3831-3836.
PMID: 29027153
Background: During heated intraperitoneal chemotherapy (HIPEC), neutropenia rates of 20 to 40% have been reported when mitomycin C (MMC) is dosed by weight or body surface area (BSA). This study...